Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence - PubMed (original) (raw)
Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence
H Meyer et al. J Gen Virol. 1991 May.
Abstract
Different passages of the vaccinia virus strain Ankara (CVA wild-type) during attenuation to MVA (modified vaccinia virus Ankara) have been analysed to detect alterations in the genome. Physical maps for the restriction enzymes HindIII and XhoI have been established. Six major deletions relative to the wild-type strain CVA could be localized. They reduce the size of the entire genome from 208 kb (CVA wild-type) to 177 kb for the MVA strain. Four deletions occurred during the first 382 passages and the resulting variant (CVA 382) displays an attenuated phenotype similar to that of the MVA strain. The deletions are located in both terminal fragments, affect two-thirds of the host range gene K1L and eliminate 3.5 kb of a highly conserved region in the HindIII A fragment. During the next 190 passages leading to MVA two additional deletions appeared. Again, one is located in the left terminal fragment, and the other includes the A-type inclusion body gene. Neither of the deletions appear to participate in further attenuation of the virus. Rescue of the partially deleted host range region with the corresponding wild-type DNA restored the ability of the attenuated strains MVA and CVA 382 to grow in some non-permissive tissue cultures. Nevertheless, the complete host range of the wild-type strain was not recovered. Also, plaque-forming behaviour and reduced virulence were not influenced. From the data presented it may be concluded that the partially deleted host range gene is not solely responsible for attenuation.
Similar articles
- Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.
Meisinger-Henschel C, Späth M, Lukassen S, Wolferstätter M, Kachelriess H, Baur K, Dirmeier U, Wagner M, Chaplin P, Suter M, Hausmann J. Meisinger-Henschel C, et al. J Virol. 2010 Oct;84(19):9907-19. doi: 10.1128/JVI.00756-10. Epub 2010 Jul 28. J Virol. 2010. PMID: 20668072 Free PMC article. - Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.
Wyatt LS, Carroll MW, Czerny CP, Merchlinsky M, Sisler JR, Moss B. Wyatt LS, et al. Virology. 1998 Nov 25;251(2):334-42. doi: 10.1006/viro.1998.9397. Virology. 1998. PMID: 9837798 - The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.
Antoine G, Scheiflinger F, Dorner F, Falkner FG. Antoine G, et al. Virology. 1998 May 10;244(2):365-96. doi: 10.1006/viro.1998.9123. Virology. 1998. PMID: 9601507 Review. - Virulence genes of poxviruses and reoviruses.
Joklik WK, Pickup DJ, Patel DD, Moody MD. Joklik WK, et al. Vaccine. 1988 Apr;6(2):123-8. doi: 10.1016/s0264-410x(88)80013-6. Vaccine. 1988. PMID: 2838983 Review.
Cited by
- Nonreplicating vaccinia vector efficiently expresses recombinant genes.
Sutter G, Moss B. Sutter G, et al. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10847-51. doi: 10.1073/pnas.89.22.10847. Proc Natl Acad Sci U S A. 1992. PMID: 1438287 Free PMC article. - Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice.
Meisinger-Henschel C, Späth M, Lukassen S, Wolferstätter M, Kachelriess H, Baur K, Dirmeier U, Wagner M, Chaplin P, Suter M, Hausmann J. Meisinger-Henschel C, et al. J Virol. 2010 Oct;84(19):9907-19. doi: 10.1128/JVI.00756-10. Epub 2010 Jul 28. J Virol. 2010. PMID: 20668072 Free PMC article. - Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus.
Jackson SS, Ilyinskii P, Philippon V, Gritz L, Yafal AG, Zinnack K, Beaudry KR, Manson KH, Lifton MA, Kuroda MJ, Letvin NL, Mazzara GP, Panicali DL. Jackson SS, et al. J Virol. 2005 May;79(10):6554-9. doi: 10.1128/JVI.79.10.6554-6559.2005. J Virol. 2005. PMID: 15858042 Free PMC article. - Preparation of cell cultures and vaccinia virus stocks.
Earl PL, Cooper N, Wyatt LS, Moss B, Carroll MW. Earl PL, et al. Curr Protoc Protein Sci. 2001 May;Chapter 5:Unit5.12. doi: 10.1002/0471140864.ps0512s13. Curr Protoc Protein Sci. 2001. PMID: 18429178 Free PMC article. - Vaccinia virus vaccines: past, present and future.
Jacobs BL, Langland JO, Kibler KV, Denzler KL, White SD, Holechek SA, Wong S, Huynh T, Baskin CR. Jacobs BL, et al. Antiviral Res. 2009 Oct;84(1):1-13. doi: 10.1016/j.antiviral.2009.06.006. Epub 2009 Jun 26. Antiviral Res. 2009. PMID: 19563829 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources